UroGen Pharma Ltd.

URGN

$675M

Small Cap

NASDAQPharmaceutical Preparations🇺🇸North AmericaRA'ANANA287 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 31, 2026

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

2 upcoming, 0 past

⭐Phase 3Next

UGN-104 Phase 3 Results Expected

Mar 31, 2026UGN-10450

Primary completion for UGN-104 trial (NCT06774131) in Upper Urinary Tract Urothelial Carcinoma

Source

⭐Phase 3

UGN-104 Phase 3 Results Expected

October 2026~UGN-10470

Primary completion for UGN-104 trial (NCT06774131) in Upper Urinary Tract Urothelial Carcinoma

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

UGN-101 instillations

Phase 3

Carcinoma, Transitional Cell

UGN-102

Phase 3

Bladder Cancer

UGN-104

Phase 3

Upper Urinary Tract Urothelial Carcinoma

UGN-103

Phase 3

Bladder Cancer

120 mg MMC in 90ml gel

Phase 2

Bladder Cancer

Drug Name	Phase	Indication	Designations
UGN-101 instillations	Phase 3	Carcinoma, Transitional Cell	-
UGN-102	Phase 3	Bladder Cancer	-
UGN-104	Phase 3	Upper Urinary Tract Urothelial Carcinoma	-
UGN-103	Phase 3	Bladder Cancer	-
120 mg MMC in 90ml gel	Phase 2	Bladder Cancer	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

URGN News